FDA Panel Backs GRAIL's Galleri Cancer Test, Clearing Key Hurdle
GRAL has more than doubled off its 52-week low of $41.5 on elevated volume (4.0× avg).
Summary
The FDA advisory committee voted in favor of GRAIL's Galleri multi-cancer early detection test, with a 7-2 (1 abstention) vote that benefits outweigh risks, unanimous support on safety, and 6-4 on effectiveness. This is a major regulatory milestone for the first PMA submission of its kind, and while the FDA is not bound by the vote, it typically follows panel recommendations. The positive vote follows a broadly supportive FDA briefing document released two days ago and a trading halt earlier today. Final FDA decision is expected in the coming months, and approval would open a large screening market for adults 50+.
At the time of this announcement, GRAL was trading at $108.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $41.50 to $118.84. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: PR Newswire.